entertainment -WSS

entertainment

author：entertainment 2025-09-03 11:49:57 - browse：785

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Medicare threatens to cut off funding for HCA's Mission hospital

WSS

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Key House Republican on health care plans exit from Congress

KalVista pill reduced swelling 'attacks' caused by genetic disease

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Trump pressured former Arizona governor to overturn 2020 election results: Sources

The dental labor crisis is a moment of opportunity

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

The cancer drug shortage isn’t new — and neither are the solutions

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

State Dept. review finds Biden bears some blame for Afghanistan failures

A disappointing year of Humira biosimilars

Heart attack and stroke risk calculators need revising

Vaccine advisory panel ACIP left half staffed by HHS

knowledge

For Medicare Advantage, Democrats want stronger protections around AI

A timeline of the missing Titanic tourist submersible

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

Noem? Reynolds? A very early look at the Republican 'veepstakes'

leisure time

knowledge

focus

hotspot